Heart Failure Reduces Both the Effects and Interaction Between Cyclic GMP and Cyclic AMP

Journal of Surgical Research

Volumn 134, Issue 2, 2006, Pages 300-306

  Moalem, Jacob ^a   Weiss, Harvey R ^a   Davidov, Tomer ^a   Rodriguez, Roberto ^a   Molino, Bruno ^a   Lazar, Michael J ^a   Scholz, Peter M ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

cardiac function; cyclic AMP; cyclic GMP; dog; heart failure; hypertrophy; myocardial oxygen consumption

Indexed keywords

8 BROMO CYCLIC GMP; CYCLIC AMP; CYCLIC GMP; ISOPRENALINE; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; HEART FAILURE; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE HYPERTROPHY; HEART WORK; INFUSION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANIMALS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CORONARY CIRCULATION; CORONARY VESSELS; CYCLIC AMP; CYCLIC GMP; DISEASE MODELS, ANIMAL; DOGS; HYPERTROPHY, LEFT VENTRICULAR; ISOPROTERENOL; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXYGEN CONSUMPTION;

EID: 33746189657     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.01.015     Document Type: Article

References (34)

1. Casadei B., and Sears C.E. Nitric-oxide-mediated regulation of cardiac contractility and stretch responses. Prog Biophys Molec Biol 82 (2003) 67
2. Shah A.M., and MacCarthy P.A. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86 (2000) 49
3. 2+-ATPase. Pharmacology 64 (2002) 106
4. 2 ACh receptor. Am J Physiol 281 (2001) C1251
5. Vila-Petroff M.G., Younes A., Egan J., Lakatta E.G., and Sollott S.J. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84 (1999) 1020
6. Wollert K.C., and Drexler H. Regulation of cardiac remodeling by nitric oxide. Focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 7 (2002) 317
7. Leone Jr. R.J., Straznicka M., Scholz P.M., and Weiss H.R. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts. Basic Res Cardiol 95 (2000) 28
8. Weiss H.R., Lazar M.J., Punjabi K., Tse J., and Scholz P.M. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes. Eur J Pharmacol 481 (2003) 25
9. Ungureanu-Longrois D., Bezie Y., Perret C., and Laurent S. Effects of exogenous and endogenous nitric oxide on the contractile function of cultured chick embryo ventricular myocytes. J Mol Cell Cardiol 29 (1997) 677
10. Joe E.K., Schussheim A.E., Longrois D., et al. Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS). Mechanisms of contractile depression by nitric oxide. J Mol Cell Cardiol 30 (1998) 303
11. Yin X., Shan Q., Deng C., and Bourreau J.P. Effect of SIN-1 in rat ventricular myocytes. Interference with beta-adrenergic stimulation. Life Sci 71 (2002) 287
12. Gustafsson A.B., and Brunton L.L. Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1beta and NO. Role of cGMP-stimulated PDE2. Am J Physiol 283 (2002) C463
13. Kojda G., and Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 41 (1999) 514
14. Hannan R.D., Jenkins A., Jenkins A., and Brandenburger Y. Cardiac hypertrophy. A matter of translation. Clin Exp Pharmacol Physiol 30 (2003) 517
15. Lorell B.H., and Carabello B.A. Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation 102 (2000) 470
16. Scholz P.M., Upsher M.E., Eliades E., Kedem J., and Weiss H.R. Alteration in the regional β-adrenergic system in experimental left ventricular hypertrophy. Cardiovasc Res 24 (1990) 65
17. Yarbrough W.M., and Spinale F.G. Large animal models of congestive heart failure. A critical step in translating basic observations into clinical applications. J Nucl Cardiol 10 (2003) 77
18. Brodde O.E. β-Adrenergic receptors in failing human myocardium. Basic Res Cardiol 91 Suppl. II (1996) 35
19. Ritter O., and Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med 9 (2003) 313
20. Wallukat G. The beta-adrenergic receptors. Herz 27 (2002) 683
21. 1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy. Mol Cell Biochem 205 (2000) 67
22. Huang M.W., Weiss H.R., Tse J., Leone Jr. R.J., and Scholz P.M. Pacing-induced cardiac failure of hypertrophic hearts. Effects of cyclic GMP reduction. J Surg Res 86 (1999) 89
23. Scholz P.M., Grover G.J., Mackenzie J.W., and Weiss H.R. Regional oxygen supply and consumption balance in experimental left ventricular hypertrophy. Basic Res Cardiol 85 (1990) 575
24. Weiss H.R., Gong G.X., Straznicka M., Yan L., Tse J., and Scholz P.M. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases. Can J Physiol Pharmacol 77 (1999) 422
25. Sadoff J.D., Scholz P.M., Tse J., and Weiss H.R. Increased guanylate cyclase activity is associated with an increase in cyclic GMP in left ventricular hypertrophy. J Clin Invest 98 (1996) 838
26. Klein C. Nitric oxide and the other cyclic nucleotide. Cell Signal 14 (2002) 493
27. Kwan H.Y., Huang Y., and Yao X. Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism. J Biol Chem 275 (2000) 6758
28. Hata J.A., Williams M.L., and Koch W.J. Genetic manipulation of myocardial beta-adrenergic receptor activation and desensitization. J Molec Cell Cardiol 37 (2004) 11
29. Lohse M.J., Engelhardt S., and Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 93 (2003) 896
30. Dorn II G.W., and Molkentin J.D. Manipulating cardiac contractility in heart failure. Data from mice and men. Circulation 109 (2004) 150
31. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108 (2001) 671
32. Movsesian M.A., and Alharethi R. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin Investig Drugs 11 (2002) 1529
33. Shahid M., and Nicholson C.D. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium. Positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 342 (1990) 698
34. Huang M.W., Leone Jr. R.J., Weiss H.R., Tse J., and Scholz P.M. Effects of beta-adrenoceptor stimulation on pacing-induced failure of dog hypertrophic hearts. Clin Exp Pharmacol Physiol 27 (2000) 202